xRNA Therapies
End-to-End xRNA Production for Advanced Therapies
Recipharm Advanced Bio’s fit-for-purpose advanced therapy CDMO services, technologies, and experience provide comprehensive GMP xRNA manufacturing solutions, including plasmid DNA, xRNA, and lipid nanoparticle (LNP) production. Our team has extensive expertise in process development and manufacturing, as well as state-of-the-art equipment, allowing us to support your innovation throughout its development and ensure a stable commercial supply.
We’re dedicated to process innovation and continually finding better ways to develop complex advanced therapeutics. Our novel continuous xRNA manufacturing platform is just one of many innovations, and our global footprint means we have the capacity to meet your needs as your program develops.
Supporting the Diverse xRNA Pipeline
The application of RNA molecules to target and regulate gene expression is in its infancy; however, innovative approaches for modifying RNA molecules to inhibit the expression of disease-causing genes are advancing rapidly. ReciBioPharma has deep and growing scientific expertise across a range of molecule types.
Integrated xRNA Production Solutions
Recipharm Advanced Bio is advancing next-generation biomanufacturing with a focus on efficiency, quality, and scalability. Our approach leverages:
- Automated, high-throughput production for consistency and rapid turnaround
- Scalable GMP xRNA manufacturing from clinical to commercial volumes
- Integrated analytics to ensure product quality at every stage
We are committed to reducing manufacturing timelines and costs by providing end-to-end capabilities—paving the way for rapid action to enable both broad vaccine access and patient-specific medicines.
Dedicated process development laboratories and manufacturing capabilities with capacity from preclinical to commercial scales.
Our facilities and equipment are designed for every phase of your project, scale from 1 to 100g, and utilize a range of mixing technologies.
Recipharm Advanced Bio has extensive experience providing GMP sterile fill-finish services for customers worldwide.
Innovation Spotlight
The world’s first continuous and integrated nucleic acid manufacturing platform
Recipharm Advanced Bio’s xRNA manufacturing platform is the future of xRNA production. Grant funding by the FDA’s Center for Biologics Evaluation and Research (CBER) Advanced Technology Program and in partnership with MIT, Recipharm Advanced Bio has assembled AI-enabled production, digital control, and advanced process analytical technologies (PAT) to shorten timelines and optimize xRNA product quality.
Learn MorexRNA Resources
Advancing Your Program Together
Your program isn’t just another project—it’s a breakthrough in the making. At Recipharm Advanced Bio, we bring deep scientific expertise, innovative thinking, and a problem-solving mindset to every partnership. Whether scaling a complex process, navigating regulatory pathways, or optimizing for commercial success, we’re here to collaborate, adapt, and deliver with excellence.
Let’s push the boundaries of possibility together and bring transformative therapies to patients faster.